Generic Medicine Pharma
Erdafixen (Erdafitinib) 4mg
Erdafixen (Erdafitinib) 4mg
Erdafixen 4mg contains Erdafitinib, a targeted cancer therapy used to treat advanced or metastatic urothelial carcinoma with FGFR genetic mutations. Erdafitinib works by blocking fibroblast growth factor receptors (FGFR), which helps slow cancer cell growth and progression.
| Field | Details |
|---|---|
| Original Brand | Balversa |
| Generic Brand | Erdafixen 4 |
| Generic Name | Erdafitinib 4mg |
| Pack Size | 28 Tablets |
| Use / Indications | Advanced or Metastatic Urothelial Carcinoma (FGFR Mutation Positive) |
| Manufacturer | Everest Pharmaceuticals Ltd. (Produced in Bangladesh) |
| Status | Prescription Only Medicine |
Introduction to Balversa (Erdafitinib) 4mg
Balversa (Erdafitinib) 4mg is a targeted prescription medicine used in the treatment of certain advanced cancers, particularly urothelial carcinoma (a type of bladder cancer) that contains specific FGFR genetic mutations. This medicine belongs to a specialized group of oncology drugs that block abnormal signals responsible for cancer growth.
Balversa (Erdafitinib) 4mg is classified under Prescription Medicines, Oncology Medicines, Targeted Cancer Therapies, and Oral Anticancer Drugs. It contains Erdafitinib, which works by inhibiting fibroblast growth factor receptors (FGFR) that promote tumor cell growth.
In some markets, Erdafixen 4mg is available as a generic brand containing the same active ingredient Erdafitinib, offering a similar therapeutic effect when prescribed by a qualified healthcare professional.
What Is Balversa (Erdafitinib)?
Balversa is the brand name for Erdafitinib, an oral medication widely used for the treatment of advanced or metastatic urothelial carcinoma with FGFR genetic alterations.
Erdafitinib belongs to a class of medicines known as FGFR Inhibitors. These medicines block specific growth signals in cancer cells that drive tumor development.
Generic versions such as Erdafixen 4mg contain the same active compound and may be used depending on physician recommendation and regional availability.
Drug Class and Mechanism of Action
Erdafitinib is classified as a targeted anticancer therapy and FGFR tyrosine kinase inhibitor with antineoplastic properties.
How Erdafitinib Works
It works in several ways:
- Blocks fibroblast growth factor receptors (FGFR1–FGFR4)
- Prevents abnormal cancer cell signaling pathways
- Inhibits tumor growth and proliferation
Through these mechanisms, Erdafitinib helps slow or stop the progression of certain cancers driven by FGFR mutations.
How Balversa Works in the Body
Certain cancers grow due to abnormal activation of FGFR pathways. Balversa works by targeting these genetic mutations and blocking the signals that stimulate cancer cell growth.
Key Actions of Erdafitinib
- Blocking FGFR signaling pathways in tumor cells
- Preventing cancer cell growth and division
- Reducing tumor progression in FGFR-mutated cancers
Some generic versions such as Erdafixen deliver the same active compound, allowing similar targeted cancer treatment when prescribed appropriately.
Medical Uses of Balversa (Erdafitinib) 4mg
Balversa 4mg is prescribed for specific cancers with FGFR genetic mutations.
Balversa for Urothelial Carcinoma
Balversa is mainly used for patients with locally advanced or metastatic urothelial carcinoma who have FGFR2 or FGFR3 gene mutations.
Potential Benefits
- Targeted treatment for FGFR-mutated tumors
- Slows cancer progression
- Improves treatment options for advanced bladder cancer
Generic alternatives like Erdafixen 4mg may also be used under medical supervision when Erdafitinib therapy is recommended.
Who Can Take Erdafixen 4mg?
Because Erdafitinib is a specialized targeted therapy, treatment should always be supervised by an experienced oncologist.
Eligibility Criteria
Patients may be prescribed Balversa if they:
- Are diagnosed with advanced or metastatic urothelial carcinoma
- Have confirmed FGFR2 or FGFR3 genetic mutations
- Have previously received platinum-based chemotherapy
Certain generic options such as Erdafixen may also be considered depending on availability and physician decision.
Who Should Avoid Balversa (Erdafitinib) 4mg
Balversa should NOT be used by:
- Individuals with hypersensitivity to Erdafitinib
- Patients without confirmed FGFR mutations
- Individuals with severe uncontrolled eye disorders unless monitored by a specialist
Balversa (Erdafitinib) 4mg Dosage and Administration
Standard Dosage Guidelines
Typical dosage recommendations include:
- Balversa 4mg taken once daily
- Tablets should be swallowed whole with water
- Can be taken with or without food
Dosage Adjustments
Doctors may adjust the dose depending on:
- Blood phosphate levels
- Treatment response
- Presence of side effects
Side Effects of Balversa 4mg
Like many targeted cancer medicines, Balversa may cause side effects.
Common Side Effects
- Mouth sores or dry mouth
- Fatigue
- Nail changes
- Diarrhea
Serious Side Effects
- Eye problems (central serous retinopathy)
- High phosphate levels in blood
- Severe skin reactions
Patients should report vision changes or severe symptoms to their doctor immediately.
Storage:
Store below 25°C in a cool, dry place, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children.
Frequently Asked Questions (FAQs)
1. What type of cancer is Balversa (Erdafitinib) 4mg used for?
Balversa is mainly used to treat advanced or metastatic urothelial carcinoma with specific FGFR gene mutations.
2. Is Balversa chemotherapy?
No. Balversa is not traditional chemotherapy. It is a targeted cancer therapy that blocks FGFR signaling pathways involved in tumor growth.
3. Do patients need genetic testing before taking Erdafitinib?
Yes. Patients must undergo genetic testing to confirm FGFR mutations before starting Erdafitinib treatment.
4. Can Erdafixen 4mg be taken with food?
Yes. Erdafitinib tablets can generally be taken with or without food unless directed otherwise by a doctor.
5. Can pregnant women take Erdafixen 4mg?
No. Erdafixen 4mg should not be used during pregnancy because Erdafitinib may harm an unborn baby.
6. Is Erdafixen 4mg the same as Balversa?
Erdafixen 4mg contains Erdafitinib, the same active ingredient found in Balversa. Generic versions is available. for more info. contact on WhatsApp: https://wa.me/8801742433764
7. Do I need a prescription to buy Erdafixen (Erdafitinib) 4mg?
Yes. Erdafixen 4mg is a prescription-only medicine and should only be used under the supervision of a qualified healthcare professional.
Medical Disclaimer
Disclaimer:
The information provided on this page is for educational and informational purposes only and should not be considered medical advice. Balversa (Erdafitinib) is a prescription-only medication and must be used strictly under the supervision of a qualified healthcare professional. Always consult your physician before starting, stopping, or changing any medication.





